These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 27249005

  • 1. Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder.
    Chen SF, Chang CH, Kuo HC.
    Toxins (Basel); 2016 May 30; 8(6):. PubMed ID: 27249005
    [Abstract] [Full Text] [Related]

  • 2. Effect of detrusor botulinum toxin a injection on urothelial dysfunction in patients with chronic spinal cord injury: a clinical and immunohistochemistry study before and after treatment.
    Chen SF, Chang CH, Kuo HC.
    Spinal Cord; 2016 Oct 30; 54(10):889-894. PubMed ID: 26832760
    [Abstract] [Full Text] [Related]

  • 3. Single onabotulinumtoxinA 200U dose improved clinical symptoms but not urothelial dysfunction in neurogenic detrusor overactivity due to spinal cord injury.
    Chen SF, Jiang YH, Kuo HC.
    J Formos Med Assoc; 2019 Jan 30; 118(1 Pt 1):125-133. PubMed ID: 29482913
    [Abstract] [Full Text] [Related]

  • 4. Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury.
    Smith CP, Gangitano DA, Munoz A, Salas NA, Boone TB, Aoki KR, Francis J, Somogyi GT.
    Neurochem Int; 2008 May 30; 52(6):1068-75. PubMed ID: 18187233
    [Abstract] [Full Text] [Related]

  • 5. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
    Leitner L, Guggenbühl-Roy S, Knüpfer SC, Walter M, Schneider MP, Tornic J, Sammer U, Mehnert U, Kessler TM.
    Eur Urol; 2016 Sep 30; 70(3):522-8. PubMed ID: 27106070
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia.
    Chen CY, Liao CH, Kuo HC.
    Spinal Cord; 2011 May 30; 49(5):659-64. PubMed ID: 21243000
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity.
    Chen SF, Kuo HC.
    J Formos Med Assoc; 2015 Jul 30; 114(7):583-9. PubMed ID: 24262922
    [Abstract] [Full Text] [Related]

  • 8. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
    Chen YC, Kuo HC.
    Neurourol Urodyn; 2014 Jan 30; 33(1):129-34. PubMed ID: 23494629
    [Abstract] [Full Text] [Related]

  • 9. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
    Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C.
    Neurourol Urodyn; 2013 Nov 30; 32(8):1109-15. PubMed ID: 23389824
    [Abstract] [Full Text] [Related]

  • 10. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
    Mehta S, Hill D, McIntyre A, Foley N, Hsieh J, Ethans K, Teasell RW, Loh E, Welk B, Wolfe D.
    Arch Phys Med Rehabil; 2013 Aug 30; 94(8):1473-81. PubMed ID: 23632286
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection.
    Kuo HC.
    Urology; 2008 Nov 30; 72(5):1056-60. PubMed ID: 18533231
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
    Gamé X, Khan S, Panicker JN, Kalsi V, Dalton C, Elneil S, Hamid R, Dasgupta P, Fowler CJ.
    BJU Int; 2011 Jun 30; 107(11):1786-92. PubMed ID: 21040367
    [Abstract] [Full Text] [Related]

  • 13. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Giannantoni A, Mearini E, Del Zingaro M, Porena M.
    Eur Urol; 2009 Mar 30; 55(3):705-11. PubMed ID: 18814955
    [Abstract] [Full Text] [Related]

  • 14. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.
    Conte A, Giannantoni A, Proietti S, Giovannozzi S, Fabbrini G, Rossi A, Porena M, Berardelli A.
    Eur J Neurol; 2012 May 30; 19(5):725-32. PubMed ID: 22212295
    [Abstract] [Full Text] [Related]

  • 15. Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.
    Chen G, Liao L.
    Int Urol Nephrol; 2011 Sep 30; 43(3):655-62. PubMed ID: 21110094
    [Abstract] [Full Text] [Related]

  • 16. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
    Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D.
    J Urol; 2000 Sep 30; 164(3 Pt 1):692-7. PubMed ID: 10953127
    [Abstract] [Full Text] [Related]

  • 17. Video-Urodynamic Characteristics and Predictors of Switching from Botulinum Neurotoxin a Injection to Augmentation Enterocystoplasty in Spinal Cord Injury Patients.
    Lin CC, Kuo HC.
    Toxins (Basel); 2022 Jan 10; 14(1):. PubMed ID: 35051024
    [Abstract] [Full Text] [Related]

  • 18. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
    Cruz F, Nitti V.
    Neurourol Urodyn; 2014 Jul 10; 33 Suppl 3():S26-31. PubMed ID: 25042140
    [Abstract] [Full Text] [Related]

  • 19. Protocol for a prospective magnetic resonance imaging study on supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor overactivity.
    Leitner L, Walter M, Freund P, Mehnert U, Michels L, Kollias S, Kessler TM.
    BMC Urol; 2014 Aug 18; 14():68. PubMed ID: 25132340
    [Abstract] [Full Text] [Related]

  • 20. The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin.
    Traini C, Vannucchi MG.
    Toxins (Basel); 2019 Oct 24; 11(11):. PubMed ID: 31652991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.